Antihypertensive Therapy: Role of Aldosterone Antagonists

Author(s): Anna Maria Grandi

Journal Name: Current Pharmaceutical Design

Volume 11 , Issue 17 , 2005

Become EABM
Become Reviewer


The interest for the therapeutic potential of aldosterone antagonists in essential hypertension comes from the recently discovered nonclassical pathways of aldosterone actions, above all the presence of extra-adrenal aldosterone production and the discovery of aldosterones proinflammatory and profibrotic actions. The review begins with the discussion of experimental studies on animals, demonstrating the role of aldosterone in cardiovascular remodeling and the effects of aldosterone blockade on hypertensive target organ damage. Then recent clinical studies are presented, that confirm in humans the deleterious role of aldosterone, in particular in the development of myocardial hypertrophy, cardiovascular fibrosis and arterial stiffness. After a brief description of the new selective aldosterone antagonist, eplerenone, compared to the well-known non-selective aldosterone antagonist, spironolactone, the results of studies on essential hypertensive patients are discussed, evaluating the efficacy of aldosterone antagonists in lowering blood pressure, but, more important, in protecting against target organ damage.

Keywords: aldosterone, aldosterone antagonists, spironolactone, canrenone, eplerenone, hypertension, myocardial hypertrophy, diastolic function

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [2235 - 2242]
Pages: 8
DOI: 10.2174/1381612054367418
Price: $65

Article Metrics

PDF: 2